Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Advanced Brain-Penetrant Enzyme Therapy to Treat Lafora Disease

Award Number: R61NS146312
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Advanced Brain-Penetrant Enzyme Therapy to Treat Lafora Disease - Lafora disease (LD) is a fatal autosomal recessive neurodegenerative disorder characterized by myoclonus, seizures, and a rapid progression to dementia during the teenage years, culminating in death within a decade of onset. LD arises from mutations in genes encoding laforin, a glycogen phosphatase, or malin, an E3 ubiquitin ligase, leading to the accumulation of pathogenic polyglucosan bodies (PGBs) in the brain. Studies in LD mouse models have identified brain PGBs as the primary driver of disease sequalae, identifying the brain PGBs as the critical therapeutic target. Previously, Gentry and Vander Kooi developed an antibody-enzyme fusion (AEF) therapy that degrades brain PGBs and normalizes brain metabolism in LD mice following intracerebroventricular (ICV) administration of the AEF. This work demonstrated impressive proof-of-concept target engagement and brain metabolic recovery. However, clinical translation of this AEF was limited because it does not efficiently cross the blood- brain barrier (BBB). Wang and Gorman recently developed effective antibody-based brain shuttle platforms to allow biologic delivery across the BBB and into the brain parenchyma. This platform utilizes antibodies targeting human transferrin receptor (TfR), which enhance uptake into brain parenchyma by 10-30-fold. This R61/R33 project brings together these two novel technologies. We have engineered a brain-penetrant BBB-AEF therapeutic by fusing the TfR-targeting brain shuttle to the AEF, allowing systemic administration and robust brain PGB clearance. We demonstrate that this BBB-AEF fusion that crosses the BBB, penetrates brain parenchyma, accesses the cytoplasm, and degrades PGBs. A key feature for clinical translation is that the BBB-AEF fusions are humanized. Additionally, we have established a humanized TfR knock-in LD mouse model, designated hTfR-LKO, and developed the needed assays to assess target engagement. Thus, we have already generated preliminary data and necessary tools to develop a translational therapy. The R61 phase (1 year) will establish BBB-AEF target engagement by defining pharmacokinetics, determining an initial effective dose, and assessing PGB clearance in hTfR-LKO mice. Success will be defined by achieving >50% brain PGB degradation. The R33 phase (2 years) will refine dosing regimens to identify the minimum effective dose (MED), optimal treatment duration, and potential sex differences while evaluating physiological outcomes and preliminary safety. Success will be defined by establishing a MED and redosing parameters in both sexes along with defining the therapeutic window and physiological outcomes. This project unites complementary expertise to advance a first-in-class targeted therapeutic for LD and provides the needed data for continued development of this therapeutic. Beyond LD, this platform has the potential to facilitate brain delivery of other biologics, establishing a broadly applicable strategy for treating neurological diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $420,990 )
2026	2026	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	5/4/2026	NEW	$420,990
														Subtotal = $420,990

Grand Total All Awards = $420,990

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advanced Brain-Penetrant Enzyme Therapy to Treat Lafora Disease

Award Number: R61NS146312

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer